# Zalicus

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/zalicus

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.combinatorx.com
- Total disclosed funding: $70M
- Latest round: Series C (Mar 10, 2004)
- Investors on record: 14

## About

Zalicus Inc, operating under the brand CombinatorX, focuses on delivering innovative technological solutions, particularly advanced software platforms aimed at optimizing business operations across diverse industries.Founded in 2000 and headquartered in Cambridge, US, Zalicus Inc (CombinatorX) specializes in developing technological solutions for businesses. In March 2006, the company underwent a Trade Sale raising USD 8.00 mn from Horizon Discovery Ltd. The firm has completed a total of 14 deals, with its most recent deal dated March 24, 2006. Zalicus was formed through the entrepreneurial vision of its founders, who recognized the need for advanced operational solutions in various sectors.CombinatorX specializes in the development and provision of innovative technological solutions designed to streamline operations across various sectors. Their core product offerings focus on advanced software platforms that cater to the needs of businesses seeking to optimize workflows, enhance productivity, and improve overall operational efficiency. The company targets a diverse array of industries, including healthcare, finance, and logistics, with solutions aimed at addressing specific challenges such as data management, regulatory compliance, and resource allocation. CombinatorX's products are designed for use by corporations, small to medium enterprises, and government agencies, ensuring a broad client base that spans multiple geographical markets, including North America, Europe, and parts of Asia. By continuously evolving their offerings based on user feedback and market demands, CombinatorX strives to maintain a competitive edge in the rapidly changing technology landscape.In the most recent financial year of 2013, CombinatorX reported a revenue of USD 14.73 mn and an EBITDA of USD -27.16 mn. The company generates revenue through a combination of subscription-based models and B2B partnership agreements, with clients typically engaging in multi-year contracts that provide access to a suite of tailored software applications. This recurring revenue model fosters long-term relationships with clients across various sectors.Zalicus Inc plans to launch new product offerings aimed at enhancing their software solutions, although specific release dates remain undisclosed. The company is targeting expansion into new geographic markets, particularly in Europe and parts of Asia by the end of 2024. Recent funding from the Trade Sale will be utilized to support these initiatives and strengthen product development efforts, building on the success of their previous IPO where they raised USD 42 mn.

## Funding rounds

- Series C, Mar 10, 2004, $30M — Boston Millennia Partners, Flagship Pioneering, TL Ventures, Global Life Science Ventures, Canaan Partners, Easton Capital Investment Group, Yasuda Enterprise Development
- Series C, Sep 23, 2002, $40M — Adams Street Partners, BioVentures Investors, Flagship Pioneering, TL Ventures, CDIB Capital Group, Global Life Science Ventures, Canaan Partners, Foundation Medical Partners, Novartis Venture Fund, CDIB BioScience Venture Management, POSCO BioVentures

## Investors

- Adams Street Partners (https://capitalatlas.ai/funds/adams-street-partners) — Series C
- BioVentures Investors (https://capitalatlas.ai/funds/bioventures-investors) — Series C
- Flagship Pioneering (https://capitalatlas.ai/funds/flagship-pioneering) — Series C
- TL Ventures (https://capitalatlas.ai/funds/tl-ventures) — Series C
- CDIB Capital Group (https://capitalatlas.ai/funds/cdib-capital-group) — Series C
- Global Life Science Ventures (https://capitalatlas.ai/funds/global-life-science-ventures) — Series C
- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series C
- Foundation Medical Partners (https://capitalatlas.ai/funds/foundation-medical-partners) — Series C
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series C
- CDIB BioScience Venture Management (https://capitalatlas.ai/funds/cdib-bioscience-venture-management) — Series C
- POSCO BioVentures (https://capitalatlas.ai/funds/posco-bioventures) — Series C
- Boston Millennia Partners (https://capitalatlas.ai/funds/boston-millennia-partners) — Series C
- Easton Capital Investment Group (https://capitalatlas.ai/funds/easton-capital-investment-group) — Series C
- Yasuda Enterprise Development (https://capitalatlas.ai/funds/yasuda-enterprise-development) — Series C